- Home
- BTM vs UBX Comparison
BTM vs UBX Comparison
Compare BTM & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTM
- UBX
- Stock Information
- Founded
- BTM 2016
- UBX 2009
- Country
- BTM United States
- UBX United States
- Employees
- BTM N/A
- UBX N/A
- Industry
- BTM Finance: Consumer Services
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- BTM Finance
- UBX Health Care
- Exchange
- BTM Nasdaq
- UBX Nasdaq
- Market Cap
- BTM 23.1M
- UBX 20.4M
- IPO Year
- BTM N/A
- UBX 2018
- Fundamental
- Price
- BTM $1.41
- UBX $0.99
- Analyst Decision
- BTM Strong Buy
- UBX Strong Buy
- Analyst Count
- BTM 2
- UBX 3
- Target Price
- BTM $4.35
- UBX $5.33
- AVG Volume (30 Days)
- BTM 176.4K
- UBX 148.7K
- Earning Date
- BTM 05-13-2025
- UBX 04-22-2025
- Dividend Yield
- BTM N/A
- UBX N/A
- EPS Growth
- BTM N/A
- UBX N/A
- EPS
- BTM N/A
- UBX N/A
- Revenue
- BTM $573,703,000.00
- UBX N/A
- Revenue This Year
- BTM $7.48
- UBX N/A
- Revenue Next Year
- BTM $0.05
- UBX N/A
- P/E Ratio
- BTM N/A
- UBX N/A
- Revenue Growth
- BTM N/A
- UBX N/A
- 52 Week Low
- BTM $0.93
- UBX $0.85
- 52 Week High
- BTM $3.52
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- BTM 55.07
- UBX 37.79
- Support Level
- BTM $1.27
- UBX $0.91
- Resistance Level
- BTM $1.42
- UBX $1.07
- Average True Range (ATR)
- BTM 0.10
- UBX 0.09
- MACD
- BTM 0.01
- UBX 0.03
- Stochastic Oscillator
- BTM 89.47
- UBX 61.29
About BTM Bitcoin Depot Inc.
Bitcoin Depot Inc owns and operates the largest network of BTMs across North America where customers can buy and sell Bitcoin. Bitcoin Depot helps power the digital economy for users of cash. It has locations across the U.S. and Canada at, among others, the following types of retailers: Convenience Stores and Gas Station Chains, Pharmacies and Grocers and Mall Operators.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.